Viking Therapeutics, Inc. (LON:0VQA)

Market Cap	3.01B
Revenue (ttm)	n/a
Net Income (ttm)	-87.84M
Shares Out	n/a
EPS (ttm)	-0.81
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	14,902
Average Volume	7,814
Open	32.09
Previous Close	32.37
Day's Range	31.66 - 36.37
52-Week Range	8.79 - 99.30
Beta	n/a
RSI	51.45
Earnings Date	Feb 5, 2025

About Viking Therapeutics

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company’s lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phas...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 2012
• Employees: 27
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0VQA

Financial Performance

Financial numbers in USD